Skip to Main Content

Author Details

Robert B Diasio
Mayo Clinic
1965
245
69
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37961517Germline <i>cis</i> variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (<i>DPYD</i>).bioRxiv2024
36821823<i>DPYD</i> Testing: Time to Put Patient Safety First.J Clin Oncol2023
36848609Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine.JCO Precis Oncol2023
35804978Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.Cancers (Basel)2022
34195556Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications.Mayo Clin Proc Innov Qual Outcomes2021
33793308Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.JCO Oncol Pract2021
33491253Haplotype structure defines effects of common DPYD variants c.85T &gt; C (rs1801265) and c.496A &gt; G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.Br J Clin Pharmacol2021
34114648Pharmacogenomic-Guided Therapy in Colorectal Cancer.Clin Pharmacol Ther2021
32923881Severe Capecitabine Toxicity Associated With a Rare <i>DPYD</i> Variant Identified Through Whole-Genome Sequencing.JCO Precis Oncol2020
31852811Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).Oncologist2020
33283204Pharmacogenetic Variants in the <i>DPYD</i> and <i>TYMS</i> Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice.Arch Pharmacol Ther2020
33086767A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies.J Pers Med2020
30508081T4 extension alone is more predictive of better survival than a tumour size &gt;7 cm for resected T4N0-1M0 non-small-cell lung cancerâ¿ .Eur J Cardiothorac Surg2019
29923599Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.Clin Pharmacol Ther2019
31009811Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.J Thorac Oncol2019
29327356Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.Clin Pharmacol Ther2018
32039342Dose modification for safe treatment of a compound complex heterozygous <i>DPYD</i> variant carrier with 5-fluorouracil.JCO Precis Oncol2018
29152729Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.Clin Pharmacol Ther2018
28042238Drug metabolism and pancreatic cancer.Ann Gastroenterol2017
28295243Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.Clin Pharmacol Ther2017
29208398Future cancer research priorities in the USA: a Lancet Oncology Commission.Lancet Oncol2017
27727460Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.Clin Pharmacol Ther2017
26797288Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial.JAMA Oncol2016
26658227Association between DPYD c.1129-5923 C&gt;G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).Pharmacogenet Genomics2016
26644533Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies?J Clin Oncol2016
27708529Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.Ann Gastroenterol2016
27379945Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.Clin Adv Hematol Oncol2016
27407124Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.J Natl Compr Canc Netw2016
27578004Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.Cancer Res2016
27278667Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.Cancer Chemother Pharmacol2016
26770273Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.Therap Adv Gastroenterol2016
26979622A phosphotyrosine switch regulates organic cation transporters.Nat Commun2016
25655103Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.Clin Cancer Res2015
26648255Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Nat Commun2015
26198393Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Nat Commun2015
25985019Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.Sci Rep2015
23979523Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.Leukemia2014
25381393DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).J Natl Cancer Inst2014
24590640Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.J Clin Oncol2014
24727325Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Clin Cancer Res2014
24648345Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.Cancer Res2014
24401318microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.Mol Cancer Ther2014
24388031A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.Mayo Clin Proc2014
24107927Response to "A case of 5-FU-related severe toxicity associated with the P.Y186C DPYD variant".Clin Pharmacol Ther2014
24151090HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.Cancer2014
23079156A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Lung Cancer2013
23988873Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.Clin Pharmacol Ther2013
23510163Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population.BMC Med Genomics2013
23588312A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.Clin Pharmacol Ther2013
23328581Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.Cancer Res2013
  • 1 - 50 of 245

Recommended Authors

Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 9
Kristine R Crews
St. Jude Children's Research Hospital
Career Start Year 2001
Number of shared co-authors 12
Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 40
Mahadev Rao
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 1
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 3
Ann-Sofie Jemth
Karolinska Institutet
Career Start Year 1997
Number of shared co-authors 2
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Career Start Year 1994
Number of shared co-authors 3
Donna Voeller
Center for Cancer Research, National Cancer Institute
Career Start Year 1992
Number of shared co-authors 0
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 11
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 3
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 1
Stefan W??lfl
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University
Career Start Year 1987
Number of shared co-authors 0
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Career Start Year 1986
Number of shared co-authors 7
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 5
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 6
Mary Eileen Dolan
University of Chicago
Career Start Year 1981
Number of shared co-authors 16
Douglas D Ross
Greenebaum Comprehensive Cancer Center, University of Maryland
Career Start Year 1979
Number of shared co-authors 2
Robert H Shoemaker
National Cancer Institute
Career Start Year 1978
Number of shared co-authors 1
Scott H Kaufmann
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 32
Anne Monks
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 0
David W Hedley
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1975
Number of shared co-authors 1
James Koropatnick
Western University, Lawson Health Research Institute
Career Start Year 1975
Number of shared co-authors 0
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 7
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 11
Stephen B Howell
Moores Cancer Center and Department of Medicine, University of California
Career Start Year 1974
Number of shared co-authors 1
J??rgen Thomale
University Hospital Essen
Career Start Year 1972
Number of shared co-authors 1
Peter J Houghton
The University of Texas Health Science Center at San Antonio
Career Start Year 1971
Number of shared co-authors 5
Garth Powis
PHusis Therapeutics Inc.
Career Start Year 1970
Number of shared co-authors 5
John N Weinstein
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 13
Wolfgang Sad??e
College of Medicine, The Ohio State University
Career Start Year 1967
Number of shared co-authors 11

Collaborators

Steven M Offer
Mayo Clinic
Co-authored papers 23
Qian Shi
117902Beijing TongRen Hospital, Capital Medical University
Co-authored papers 8
Fergus J Couch
Mayo Clinic
Co-authored papers 6
Douglas F Easton
University of Cambridge
Co-authored papers 6
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 5
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 5
Howard L McLeod
Center for Precision Medicine and Functional Genomics, Utah Tech University
Co-authored papers 5
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 5
Ping Yang
Mayo Clinic
Co-authored papers 4
Alison M Dunning
Co-authored papers 4
Jianjun Liu
Co-authored papers 4
Diether Lambrechts
Co-authored papers 4
Matthias Schwab
and of Biochemistry and Pharmacy, University of Tuebingen
Co-authored papers 4
Graham G Giles
Co-authored papers 4
Grant W Montgomery
Co-authored papers 4
Esther M John
Co-authored papers 4
Nicholas G Martin
Co-authored papers 4
William E Grizzle
University of Alabama at Birmingham
Co-authored papers 4
Steven R Alberts
Mayo Clinic
Co-authored papers 4
Timothy G Lesnick
Mayo Clinic
Co-authored papers 4
Jeff A Sloan
Mayo Clinic
Co-authored papers 3
Christine B Ambrosone
Roswell Park Comprehensive Cancer Center
Co-authored papers 3
Per Hall
Co-authored papers 3
Daniel J Serie
Mayo Clinic
Co-authored papers 3
Federico Canzian
Co-authored papers 3
Susan E Hankinson
Co-authored papers 3
Al B Benson
Northwestern University Feinberg School of Medicine
Co-authored papers 3
Sundararajan Vincent Rajkumar
Co-authored papers 3
Sharyn D Baker
Ohio State University
Co-authored papers 3
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Release 1.2